CardiologyOnline.net

Cardiology Xagena

Xagena Mappa
Medical Meeting
Pneumobase.it
Onco News

Search results for "Oral anticoagulants"

Study treatments for the ACTIVE W trial of the ACTIVE ( Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events ) program have been discontinued due to a significant di ...


A two-gram fish oil supplement given daily to elderly persons prevented a decline in heart rate variability caused by tiny, dangerous airborne pollutant particles. Heart rate variability, a measure ...


Initial results from a phase 2 proof-of-concept study of Andexanet alfa, investigational factor Xa inhibitor antidote, in healthy volunteers who were administered the factor Xa inhibitor Rivaroxaban ( ...


The Committee for Medicinal Products for Human Use ( CHMP ) has adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Pradaxa ( Dabigat ...


If percutaneous coronary intervention ( PCI ) is required in patients taking oral anticoagulants, antiplatelet therapy with Acetylsalicylic acid ( Aspirin ) and Clopidogrel ( Plavix ) is indicated, bu ...


The WOEST ( What is the Optimal Antiplatelet and Anticoagulant Therapy in Patients With Oral Anticoagulation and Coronary Stenting ) trial randomized 573 patients on oral anticoagulants undergoing ste ...


The European Society of Cardiology ( ESC ) has published a position paper on the topic of triple therapy that shows great similarity to North American recommendations: diminished intensity of anticoag ...


Four new oral anticoagulants compare favourably with Warfarin ( Coumadin ) for stroke prevention in patients with atrial fibrillation; however, the balance between efficacy and safety in subgroups nee ...


The American Association for Thoracic Surgery ( AATS ) has released new evidence-based guidelines for the prevention and treatment of perioperative and postoperative atrial fibrillation ( POAF ) and f ...


At the end of two previous trials, an excess of stroke and bleeding was observed in patients with atrial fibrillation randomized to a new oral anticoagulant ( NOAC ) who transitioned to a vitamin K an ...


The coagulation system contributes greatly to the evolution of myocardial infarction ( MI ). Anticoagulation may reduce the occurrence of myocardial infarction as monotherapy or with concomitant use o ...


With the introduction of novel oral anticoagulants ( NOACs ), the factors driving anticoagulant selection in atrial fibrillation ( AF ) in real-world practice are unclear. The goal was to examine ...


At the end of two previous trials, an excess of stroke and bleeding was observed in patients with atrial fibrillation randomized to a new oral anticoagulant ( NOAC ) who transitioned to a vitamin K an ...


New oral anticoagulants for stroke prevention in atrial fibrillation were developed to be given in fixed doses without the need for the routine monitoring that has hindered usage and acceptance of vit ...


The new oral anticoagulants ( NOACs ) Dabigatran etexilate ( Pradaxa ), Rivaroxaban ( Xarelto ), and Apixaban ( Eliquis ) show similar efficacy for stroke prevention in patients with atrial fibrillati ...